KB
CELG

Kimelman & Baird’s Celgene Corp CELG Stock Holding History

Kimelman & Baird’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,700
Closed -$394K – 123
2017
Q3 		$394K Hold
2,700
– – 0.06% 91
2017
Q2 		$351K Hold
2,700
– – 0.05% 95
2017
Q1 		$336K Sell
2,700
-100
-4% -$12K 0.05% 93
2016
Q4 		$324K Buy
+2,800
New +$312K 0.05% 93

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Kimelman & Baird's CELG Position: Q4 2017 in Review

Kimelman & Baird sold out of Celgene Corp (CELG) in Q4 2017, closing a stake of 2,700 shares — an estimated $394K sold.

Kimelman & Baird first reported a position in CELG in Q4 2016 and held it in 4 quarters. The position peaked at $394K in Q3 2017. 1,470 funds tracked by Wall St. Rank hold CELG as of Q4 2017.

  • Kimelman & Baird reported no remaining Celgene Corp position as of Q4 2017 after selling out during the quarter.
  • Kimelman & Baird sold 2,700 Celgene Corp shares in Q4 2017, an estimated $394K.
  • Kimelman & Baird first reported a position in Celgene Corp in Q4 2016 and held it in 4 quarters.
  • Kimelman & Baird's Celgene Corp position peaked at $394K in Q3 2017.
  • 1,470 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2017.

Based on Kimelman & Baird's 13F filing for Q4 2017, filed 6 Mar 2018.